INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript

SA Transcripts158.7K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease February 27, 2026 9:30 AM EST Company Participants David Moss - President, CEO, Treasurer, Secretary & DirectorChristopher Barnum Conference Call Participants Michael WoodwardSharon Cohen - Toronto Memory Program Presentation David MossPresident, CEO, Treasurer, Secretary & Director Good morning, everyone. I'm David Moss, CEO of INmune Bio. Thank you for joining us today. INmune Bio is a clinical stage biotechnology company developing therapies that target neuroinflammation in neurodegenerative disease. Our lead program, XPro1595 is a first-in-class selective soluble TNF inhibitor. It works by blocking the form of TNF that drives pathology while preserving the form that supports normal immune function. That distinction is central to everything you'll hear today. The objective of today's webinar is straightforward to demonstrate how clinical results of our Phase II MINDFuL trial directly forge the blueprint for our registration program. Following a very productive end of Phase II meeting with the FDA, I am very pleased to report that we reached alignment on the core elements of our Phase III registration program. Today, we'll walk you through the data-driven rationale and the optimized design that will carry XPro through this final stage of clinical derisking. The MINDFuL trial was strategic lean proof-of-concept designed to solve for 2 critical variables, biologic signal and patient selection. The trial was a first of its kind, a short, small enriched population study in Alzheimer's disease. It was designed to answer 2 specific questions. Does XPro show biologic activity in patients with AD and biomarkers of inflammation? And can we identify the right patient population for a registration trial? The answer to both was yes, providing us with a validated precision medicine road map for a Phase III registration program. The data from MINDFuL directly informed